South Korea Procalcitonin Market Size & Outlook, 2025-2033
South Korea Procalcitonin Market Insights
- As per Reed Intelligence insights, the South Korea Procalcitonin Market stood at USD 3.06 Million in 2024 and is anticipated to grow to USD 9.98 Million by 2033.
- The South Korea market is expected to advance at a CAGR of 14.03% from 2026 through 2033.
- In 2024, Procalcitonin Antigen accounted for the highest share of the By Product Type market size.
- During the forecast period, Procalcitonin Antibody is set to register the highest growth, making it the most lucrative By Product Type segment.
![South Korea Procalcitonin Market Size, Share & Growth Report By [2033]](https://reedintelligence.com/uploads/charts/korea-procalcitonin-market-korea-by-product-type-42384.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, South Korea accounted for 1.19% of the global Procalcitonin Market size.
- By 2033, United States is expected to lead the global Procalcitonin Market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Procalcitonin Market size by 2033.
- India is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 29.38 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 3.06 Million |
| Market Size In 2033 | USD 9.98 Million |
| Largest segment | Procalcitonin Antigen |
| Units | Revenue in USD Million |
| CAGR | 14.03% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| By Technology |
|
| By Applications |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
South Korea Procalcitonin Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procalcitonin Antigen | XX.x | XX.x | XX.x | 1.69 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Procalcitonin Antibody | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Korea Procalcitonin Market By Technology 2025-2033 (USD Million)
| By Technology | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemiluminescence Immunoassay (CLIA) | XX.x | XX.x | XX.x | 1.4 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Enzyme-Linked Fluorescent Assay (ELFA) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Korea Procalcitonin Market By Applications 2025-2033 (USD Million)
| By Applications | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical | XX.x | XX.x | XX.x | 1.43 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Scientific Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Korea Procalcitonin Market By End-User 2025-2033 (USD Million)
| By End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 1.53 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Point-of-Care Testing (POCT) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
